PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Division of Infectious Diseases, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.\', \'Department of Medicine, VA Greater Los Angeles Healthcare System, Los Angeles, California, USA.\', \'Clinical and Translational Science Institute Office of Clinical Research, Department of Medicine, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles, California, USA.\', \'Amarex Clinical Research, LLC, Germantown, Maryland, USA.\', \'Vaccine and Gene Therapy Institute and Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, Oregon, USA.\', \'Department of Microbiology, Immunology, and Molecular Genetics, David Geffen School of Medicine at the University of California Los Angeles, Los Angeles California, USA.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1093/cid/ciaa1583
?:hasPublicationType
?:journal
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
is ?:pmid of
?:pmid
?:pmid
  • 33079180
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • -1.0
?:rankingScore_hIndex
  • -1
is ?:relation_isRelatedTo_publication of
?:title
  • Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Patients Who Received Compassionate-Use Leronlimab.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/33079180>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/33079180>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all